Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for ROCHE

All Data per March 2, 2023

Industry:

Drug Manufacturers—General

Last Close:

273.85 CHF

Expected Dividend:

3.51 %

Payoffs per Year:

1.0
Business Summary
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Competitors View

Ordering

ABBVIE

USA		 1.03 4.28%
3.61%		 7.39% 5.46% 1.0 4.36
-9.47%		 43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN		 0.96 2.56%
0.0%		 22.5% 6.68% 1.0 4.24
-32.13%		 32.9 15.38% 77.21 2.0

PFIZER

USA		 0.95 3.64%
3.96%		 2.76% 3.76% 1.0 3.02
-11.11%		 49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR		 1.04 4.07%
2.74%		 1.15% 3.92% 1.0 11.56
-3.86%		 98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN		 1.05 4.24%
0.0%		 0.0% 3.88% 1.0 8.15
-17.26%		 35.15 18.52% 61.0 5.0

SANOFI

FRA		 1.01 3.78%
4.03%		 0.74% 3.58% 1.0 0.57
-12.18%		 51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA		 0.98 2.8%
3.1%		 1.83% 2.78% 1.0 0.5
-24.44%		 34.92 17.8% 32.88 7.0

MERCK & CO.

USA		 1.12 3.12%
2.64%		 2.24% 3.15% 1.0 2.31
-11.68%		 55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN		 0.96 1.88%
1.67%		 7.74% 2.44% 1.0 3.6
-15.61%		 35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA		 1.16 2.74%
3.6%		 5.91% 3.26% 1.0 0.15
-42.43%		 33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA		 1.04 2.43%
1.22%		 2.86% 2.52% 1.0 7.52
-12.71%		 42.91 5.87% 18.4 11.0

ROCHE

CHE
 0.92 3.28%
3.51%		 0.79% 3.11% 1.0 1.4
-15.85%		 37.23 2.14% 26.53 12.0

AMGEN

USA		 1.0 2.42%
3.28%		 8.46% 3.24% 1.0 3.5
-9.93%		 35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR		 0.96 5.37%
5.27%		 0.35% 5.0% -0.5 0.21
-24.56%		 49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN		 0.96 2.43%
0.0%		 1.74% 2.4% 1.0 1.09
-19.06%		 27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN		 0.93 2.21%
2.54%		 0.0% 2.02% 1.0 -0.41
-14.62%		 28.52 12.2% 71.29 16.0

BAYER

GER		 1.02 2.51%
3.99%		 4.7% 2.83% 0.5 -0.36
-58.76%		 36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA		 0.98 2.68%
0.0%		 0.0% 2.46% 1.0 -1.0
13.03%		 44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP		 0.98 1.5%
nan%		 4.84% 1.7% -0.5 0.24
-46.29%		 31.86 -1.95% 31.7 nan

Information for ROCHE

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2012 184.00 6.80 3.70
2013 249.20 7.35 2.95
2014 269.90 7.80 2.89
2015 276.40 8.00 2.89
2016 232.60 8.10 3.48
2017 246.50 8.20 3.33
2018 243.40 8.30 3.41
2019 314.00 8.70 2.77
2020 309.00 9.00 2.91
2021 379.10 9.10 2.40
2023 273.85 9.61 3.51

Fundamentals

Chart